Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymulin, a zinc-dependent hormone.

J F Bach1, M Dardenne

  • 1INSERM 25, Hôpital Necker, Paris, France.

Medical Oncology and Tumor Pharmacotherapy
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[T CD57+ lymphocytes in kidney transplanted patients. Phenotypic and functional study].

Presse medicale (Paris, France : 1983)·1992
Same author

[Routine application of HLA class II oligotyping. Value of automatization].

Presse medicale (Paris, France : 1983)·1992
Same author

Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome.

Transplantation·1992
Same author

Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus.

The Journal of clinical investigation·1992
Same author

A1B8DR3-associated CD8-positive T-cell expansion in HIV infection.

Lancet (London, England)·1992
Same author

[A new approach of prevention: predictive medicine].

Pathologie-biologie·1992
Same journal

Treatment of ovarian cancer: the state of the art.

Medical oncology and tumor pharmacotherapy·1993
Same journal

Clinical evaluation of the CORDIS vascular access port systems: a multicenter study.

Medical oncology and tumor pharmacotherapy·1993
Same journal

Expression of an adhesion molecule and homing in B-cell chronic lymphocytic leukaemia: I. Application of the HEV-binding assay to a clinical series.

Medical oncology and tumor pharmacotherapy·1993
Same journal

Ultrastructural investigation of DNA in megakaryoblastic leukemia by using osmium-ammine-B: comparison with several types of leukemia.

Medical oncology and tumor pharmacotherapy·1993
Same journal

T-lymphocyte sub-populations in orbito-ocular granulocytic sarcoma (OOGS) and acute myelocytic leukemia (AML): a preliminary study.

Medical oncology and tumor pharmacotherapy·1993
Same journal

Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma.

Medical oncology and tumor pharmacotherapy·1993
See all related articles

Thymulin, a zinc-dependent peptide hormone, stimulates T-cell differentiation and function. Its potent effects on suppressor T-cells suggest significant future clinical applications as an immunoregulatory agent.

Area of Science:

  • Immunology
  • Endocrinology
  • Biochemistry

Background:

  • Thymulin, previously known as FTS, is a nonapeptide hormone secreted by thymic epithelial cells.
  • Its biological activity is intrinsically linked to the presence of zinc, forming an active metallopeptide.
  • The thymus plays a crucial role in T-cell development and immune regulation.

Purpose of the Study:

  • To investigate the immunomodulatory effects of thymulin.
  • To explore the potential clinical applications of thymulin, particularly its impact on T-cell subsets.
  • To highlight thymulin's role as a potential immunoregulatory agent.

Main Methods:

  • Characterization of thymulin as a zinc-dependent nonapeptide.
  • Assessment of thymulin's ability to induce T-cell differentiation.

Related Experiment Videos

  • Evaluation of thymulin's effects on various T-cell functions in vivo.
  • Analysis of thymulin's impact on suppressor T-cells.

    • Main Results:

    • Thymulin induces T-cell differentiation and enhances the function of diverse T-cell subsets.
    • The metallopeptide exhibits a particularly significant effect on suppressor T-cells.
    • Synthetic thymulin is available and demonstrates a favorable safety profile.

    Conclusions:

    • Thymulin is a potent immunoregulatory hormone with significant therapeutic potential.
    • Its ability to modulate T-cell responses, especially suppressor T-cells, positions it for future clinical use.
    • Thymulin represents a promising agent for managing immune system dysfunctions.